Global Nuclear Medicine Market Report 2013-2017 -- DUBLIN, December 27, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/tn88ln/nuclear_medicine) has announced the addition of the "Global Nuclear Medicine Market Report 2013-2017" report to their offering. The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lion's share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope. Furthermore, the PET market will witness a double digit growth during the forecast period. The therapeutic segment contributes only 10% to the global radiopharmaceuticals market and I-131 has been considered as the gold standard for various oncology treatments in a combined therapy. Global nuclear medicines market is majorly driven by the increasing adoption of PET and SPECT scanners, and rising awareness for radiopharmaceuticals, whereas short half life of isotopes and stringent regulations are the factors that are hindering the growth of radiopharmaceuticals worldwide. Besides highly preferred isotopes such as Tc-99m and F-18, significant growth is witnessed for Tl-201 and Rb-82 in diagnostic market and Y-90 and Lu-177 in beta therapy radioisotopes market. Exhaustive pipeline analysis reveals that coronary heart disease, Alzheimer's disease, breast cancer, and bone metastasis will drive the diagnostic radiopharmaceuticals market, whereas lymphoma, prostate cancer, bone metastasis, and hepatocellular carcinoma will boost the future of therapeutic radiopharmaceuticals. Besides new applications, the potential molecules that are expected to drive the market include Alpharadin (Ra-223), Ga-68, F-18 florbetapir, and F-18 choline. Though Ra-223 application is still under clinical trial, the market is highly optimistic regarding its clinical efficiency in prostate cancer, and bone metastasis. 3 Market Overview 3.1 Definition Of Radiopharmaceuticals 3.2 Evolution 3.3 Market Segmentation 3.4 Market Dynamics 3.5 Winning Imperatives 3.6 Burning Issues 3.7 Market Share Analysis 3.8 Value Chain Analysis 3.9 Pipeline Analysis 3.10 Demand & Supply Analysis 3.11 Strategic Benchmarking 3.12 Regulatory Affairs 4 Global Radiopharmaceuticals Market, By Value 4.1 Introduction 4.2 Diagnostic Market 4.3 Therapeutic Market 5 Global Radiopharmaceuticals Market, By Procedural Volume 5.1 Introduction 5.2 Diagnostic Market 5.3 Therapeutic Market 6 Radiopharmaceuticals Market, By Application/Indication 6.1 Introduction 6.2 Diagnostic Market 6.3 Therapeutic Application 7 Enriched Stable Isotopes Market 7.1 Introduction 7.2 Market Overview 7.3 Market Dynamics 7.4 Enriched Stables Market, By Isotopes 7.5 Enriched Stables Market, By Applications 8 Geographic Analysis 8.1 Introduction 8.2 Diagnostic Market 8.3 Therapy Market 8.4 Enriched Stable Isotopes Market 9 Competitive Landscape 9.1 Introduction 9.2 Mergers & Acquisitions 9.3 Agreements, Partnerships, Collaborations & Joint Ventures 9.4 Products Launch 9.5 Expansions 9.6 Other Developments 9.7 Approvals Bracco Imaging SPA Cambridge Isotope Laboratories, Inc Cardinal Health, Inc Covidien, Plc Eczacibasi-Monrol Fujifilm Holdings Corporation Ge Healthcare (Subsidiary Of General Electric Company) Iba Group Isotec, Inc (Sigma-Aldrich) Lantheus Medical Imaging, Inc Nordion, Inc Ntp Radioisotopes (PTY), Ltd Petnet Solutions, Inc (A Subsidiary Of Siemens Medical Solutions Usa, Inc) Rotem Industries, Ltd, Inc Taiyo Nippon Sanso Corporation Urenco Limited For more information visit http://www.researchandmarkets.com/research/tn88ln/nuclear_medicine